Skip to main content

Human CD23/Fc epsilon RII Alexa Fluor™ Plus 488-conjugated Antibody

R&D Systems, part of Bio-Techne | Catalog # FAB123AFP488

Catalog #
Availability
Size / Price
Qty
Loading...
FAB123AFP488-100UG

Key Product Details

Species Reactivity

Human

Applications

Immunohistochemistry, Western Blot, Blockade of Receptor-ligand Interaction, Flow Cytometry, CyTOF-ready

Label

Alexa Fluor Plus 488 (Excitation = 493 nm, Emission = 518 nm)

Antibody Source

Monoclonal Mouse IgG1 Clone # 138628

Product Specifications

Specificity

Detects human CD23/Fc epsilon RII in direct ELISAs and Western blots.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Applications

Application
Recommended Usage

Blockade of Receptor-ligand Interaction

Optimal dilution of this antibody should be experimentally determined.

CyTOF-ready

Optimal dilution of this antibody should be experimentally determined.

Flow Cytometry

Optimal dilution of this antibody should be experimentally determined.

Immunohistochemistry

Optimal dilution of this antibody should be experimentally determined.

Western Blot

Optimal dilution of this antibody should be experimentally determined.

Background: CD23/Fc epsilon RII

CD23 (also named B cell differentiation antigen) is a member of subgroup II of the C-type (Ca++-dependent) lectin superfamily (1‑5). Human CD23 is a 47 kDa type II transmembrane glycoprotein that is expressed by a wide variety of cell types (6‑10). The full-length receptor is 321 amino acids (aa) in length and contains a 274 aa extracellular region, a 26 aa transmembrane segment, and a 21 aa cytoplasmic domain. The extracellular region contains a C-type lectin domain and a connecting stalk with coiled-coil topography (3, 11). The lectin domain binds both protein and carbohydrate in an apparently Ca++ independent manner (11). The coiled-coil region contributes to oligomerization (11, 12). The lectin domain in human CD23 (aa 162‑284) is 64%, 62% and 68% aa identical to the lectin domains in mouse, rat and bovine CD23, respectively. In the cytoplasmic region, two FC isoforms exist which arise from alternate start sites (6, 12). The “a” (or long) isoform begins with the sequence MEEGQYS and is constitutively expressed by B cells. It is believed to participate in IgE-mediated endocytosis (13). The “b” (or short) isoform begins with MNPPSQ and is induced on a wide variety of cell types by IL-4 (6). Fcb reportedly contributes to IgE-mediated phagocytosis (13). Fcb expressing cells include eosinophils, monocytes, visceral smooth muscle and intestinal epithelium (6, 14, 15). At least four soluble forms of CD23 are known to exist. They range in molecular weight from 25 kDa to 37 kDa, with the 25 kDa form predominating in sera (16). Soluble CD23 (sFc) is generated by metalloprotease (ADAM8; ADAM15; ADAM28) and cysteine-protease activity (16‑18). Cleavage usually occurs between aa 150‑160 (7, 8). It is unclear if sequential metalloprotease-cysteine protease activity is necessary for the generation of all soluble forms. Both soluble and membrane-bound CD23 show bioactivity. Ligands for CD23 include CD21, IgE, CD11b, and CD11c (19‑21). CD23 binding to CD11b and Cd11c on monocytes results in oxidative product generation and proinflammatory cytokine release (21). On B cells, sCD23 induces IgE secretion by binding CD21. Conversely, secreted IgE will, in turn, bind B cell membrane CD23, rendering it unavailable for cleavage, and thus shutting down IgE production (11).

References

  1. Kijimoto-Ochiai, S. (2002) Cell. Mol. Life Sci. 59:648.
  2. Heyman, B. (2000) Annu. Rev. Immunol. 18:709.
  3. Bajorath, J. and A. Aruffo (1996) Protein Sci. 5:240.
  4. Drickamer, K. (1993) Curr. Opin. Struct. Biol. 3:393.
  5. Drickamer, K. (1999) Curr. Opin. Struct. Biol. 9:585.
  6. Yokota, A. et al. (1988) Cell 55:611.
  7. Ludin, C. et al. (1987) EMBO J. 6:109.
  8. Ikuta, K. et al. (1987) Proc. Natl. Acad. Sci. USA 84:819.
  9. Kikutani, H. et al. (1986) Cell 47:657.
  10. Letellier, M. et al. (1988) J. Immunol. 141:2374.
  11. Hibbert, R.G. et al. (2005) J. Exp. Med. 202:751.
  12. Beavuil, A.J. et al. (1992) Proc. Natl. Acad. Sci. USA 89:753.
  13. Yokota, A. et al. (1992) Proc. Natl. Acad. Sci. USA 89:5030.
  14. Belleau, J.T. et al. (2005) Clin. Mol. Allergy 3:6.
  15. Tu, Y. et al. (2005) Gastroenterology 129:928.
  16. Marolewski, A.E. et al. (1998) Biochem. J. 333:573.
  17. Fourie, A.M. et al. (2003) J. Biol. Chem. 278:30469.
  18. Karagiannis, S.N. et al. (2001) Immunology 103:319.
  19. Aubry, J-P. et al. (1992) Nature 358:505.
  20. Sarfati, M. and G. Delespeese (1988) J. Immunol. 141:2195.
  21. Lecoanet-Henchoz, S. et al. (1995) Immunity 3:119.

Long Name

Fc epsilon Receptor II

Alternate Names

CD23, CLEC4J, Fc epsilon RII, FCER2, Fcer2a, FceRII, IGEBF, Ly-42

Entrez Gene IDs

2208 (Human); 14128 (Mouse); 171075 (Rat)

Gene Symbol

FCER2

UniProt

Additional CD23/Fc epsilon RII Products

Product Documents

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices


This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is conditioned on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not (1) use this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; or (c) manufacturing or quality assurance or quality control, and/or (2) sell or transfer this product or its components for resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com.

For research use only

Loading...
Loading...
Loading...
Loading...
Loading...
Loading...